Exploring the Use of Pyridostigmine for Treating Pediatric Chronic Intestinal Pseudo-Obstruction in a Patient with ACTL6B Mutation: A Case Study and Literature Review - Scorecard - MDSpire

Exploring the Use of Pyridostigmine for Treating Pediatric Chronic Intestinal Pseudo-Obstruction in a Patient with ACTL6B Mutation: A Case Study and Literature Review

  • By

  • Immacolata Rulli

  • Angelo Mattia Carcione

  • Claudio Romano

  • Roberto Chimenz

  • Valeria Chirico

  • Lucia Marseglia

  • Carmelo Romeo

  • Eloisa Gitto

  • April 23, 2026

  • 0 min

Share

Clinical Scorecard: Exploring the Use of Pyridostigmine for Treating Pediatric Chronic Intestinal Pseudo-Obstruction in a Patient with ACTL6B Mutation: A Case Study and Literature Review

At a Glance

CategoryDetail
ConditionPediatric Chronic Intestinal Pseudo-Obstruction (PIPO)
Key MechanismsImpaired coordination of the enteric nervous system and/or intestinal smooth muscle leading to severe dysmotility.
Target PopulationPediatric patients with ACTL6B mutations and gastrointestinal dysmotility.
Care SettingPediatric gastroenterology and neurology clinics.

Key Highlights

  • PIPO is a rare, severe gastrointestinal motility disorder.
  • Pyridostigmine has shown potential benefits in managing gastrointestinal symptoms.
  • ACTL6B mutations are linked to neurodevelopmental disorders with possible gastrointestinal manifestations.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis based on exclusion of mechanical obstruction and evidence of neuromuscular dysfunction.
  • Identification of genetic or metabolic abnormalities.

Management

  • Consider pyridostigmine as adjunctive therapy in PIPO with suspected neuropathic etiology.

Monitoring & Follow-up

  • Monitor for clinical response and tolerability to pyridostigmine.

Risks

  • Adverse effects of pyridostigmine include cholinergic symptoms such as abdominal cramps and diarrhea.

Patient & Prescribing Data

Children with ACTL6B mutations and chronic intestinal pseudo-obstruction.

Pyridostigmine improved enteral feeding tolerance and reduced vomiting episodes.

Clinical Best Practices

  • Carefully titrate pyridostigmine dosage based on clinical response.
  • Caution in patients with asthma due to risk of bronchoconstriction.

References

Original Source(s)

Exploring the Use of Pyridostigmine for Treating Pediatric Chronic Intestinal Pseudo-Obstruction in a Patient with ACTL6B Mutation: A Case Study and Literature Review

  • by Immacolata Rulli, Angelo Mattia Carcione, Claudio Romano, Roberto Chimenz, Valeria Chirico, Lucia Marseglia, Carmelo Romeo, Eloisa Gitto

  • April 23, 2026

Related Content

Treatment Intensity in the Frontline Setting for Transplant-Ineligible Patients With Multiple Myeloma

The management of newly diagnosed transplant-ineligible multiple myeloma remains challenging, in part due to the complexity of treatment decisions for frail patients. Recent subgroup analyses provide insight into whether quadruplet therapy may offer advantages over triplet therapy in this population.

The risk of neoplasms in appendiceal abscess: what emergency surgeons should know

Evaluation of Treatment Efficacy, Follow-Up Outcomes, and Recurrence Trends in Pediatric Helicobacter pylori Infections